{"commentary":{"count":90,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":42,"podcast":32,"x_thread":15,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04711252\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SERENA-4","nct_id":"NCT04711252","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=serena-4-nct04711252. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SERENA-4","arms":[{"description":"The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (1 mg, PO, once daily)","label":"AZD9833 + palbociclib","type":"EXPERIMENTAL"},{"description":"The patients will recieve Anastrozole (1 mg, PO, once daily) + palbociclib (PO, once daily, 125 mg for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)","label":"Anastrozole + palbociclib","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-02-01","type":"ESTIMATED"},"conditions":["ER-Positive HER2-Negative Breast Cancer"],"enrollment":{"count":1371,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"AZD9833","type":"DRUG"},{"name":"Anastrozole","type":"DRUG"},{"name":"Anastrozole placebo","type":"DRUG"},{"name":"AZD9833 placebo","type":"DRUG"},{"name":"Palbociclib","type":"DRUG"},{"name":"Luteinizing hormone-releasing hormone (LHRH) agonist","type":"DRUG"}],"last_update":"2026-09-28","lead_sponsor":"AstraZeneca","official_title":"SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) Plus Palbociclib Versus Anastrozole Plus Palbociclib for the Treatment of Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-06-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1","timeFrame":"From randomization until progression per RECIST 1.1 as assessed by the investigator at local site or death due to any cause (up to 5 years)"}],"references":[],"start_date":{"date":"2021-01-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","url":"https://clinicaltrials.gov/study/NCT04711252"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/serena-4-nct04711252"}